Revolution Medicines, Inc. (RVMD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Mark A. Goldsmith M.D., Ph.D.
|
CEO, President & Chairman | 1.71M | -- | 1962 |
|
Mr. Jack Anders
|
Chief Financial Officer | 874.13k | 1.11M | 1977 |
|
Ms. Margaret A. Horn J.D.
|
Chief Operating Officer | 1.02M | -- | 1963 |
|
Mr. Jeffrey Cislini J.D.
|
Senior VP, General Counsel & Corporate Secretary | 791.75k | 591.85k | 1975 |
|
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.
|
Senior Advisor | 1.09M | 6.06M | 1961 |
|
Dr. Martin D. Burke M.D., Ph.D.
|
Co-Founder & Chairman of Scientific Advisory Board | -- | -- | -- |
|
Dr. Michael A. Fischbach Ph.D.
|
Academic Co-Founder & Member of Scientific Advisory Board | -- | -- | 1981 |
|
Dr. Kevan M. Shokat Ph.D.
|
Academic Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
|
Mr. Walter Reiher Ph.D.
|
Chief Information Officer | -- | -- | -- |
|
Ms. Jan Smith Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
Revolution Medicines, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 883
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Corporate Governance
Upcoming Events
November 4, 2026 at 8:00 PM UTC
Revolution Medicines, Inc. Earnings Date
